OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement
Executive Summary
OSI Pharmaceuticals is developing an intravenous formulation of its investigational anticancer agent Tarceva, which should facilitate reimbursement for the investigational anticancer agent
You may also be interested in...
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich
Erbitux BLA Resubmission Plan Set; Will Test Accelerated Approval Rules
Bristol and ImClone will take advantage of FDA's new accelerated approval interpretation in resubmitting the BLA for the oncology agent Erbitux